The Pathogenesis of Classical Hodgkin's Lymphoma: A Model for B-Cell Plasticity

Hematology/Oncology Clinics of North America

Volumn 21, Issue 5, 2007, Pages 787-804

  Mathas, Stephan ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD30 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR PAX5;

B LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; COMPLEX FORMATION; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; NONHUMAN; PATHOGENESIS; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

B-LYMPHOCYTES; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; PHENOTYPE; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 34748891176     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.016     Document Type: Review

References (109)

1. Matthias P., and Rolink A.G. Transcriptional networks in developing and mature B cells. Nat Rev Immunol 5 6 (2005) 497-508
2. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 22 (2004) 55-79
3. Kee B.L., Quong M.W., and Murre C. E2A proteins: essential regulators at multiple stages of B-cell development. Immunol Rev 175 (2000) 138-149
4. Lin H., and Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 376 6537 (1995) 263-267
5. Sigvardsson M., Clark D.R., Fitzsimmons D., et al. Early B-cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter. Mol Cell Biol 22 24 (2002) 8539-8551
6. Nutt S.L., Eberhard D., Horcher M., et al. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol 20 1 (2001) 65-82
7. Rolink A.G., Schaniel C., Bruno L., et al. In vitro and in vivo plasticity of Pax5-deficient pre-B I cells. Immunol Lett 82 1-2 (2002) 35-40
8. Ikawa T., Kawamoto H., Wright L.Y., et al. Long-term cultured E2A-deficient hematopoietic progenitor cells are pluripotent. Immunity 20 3 (2004) 349-360
9. Xie H., Ye M., Feng R., et al. Stepwise reprogramming of B cells into macrophages. Cell 117 5 (2004) 663-676
10. Laiosa C.V., Stadtfeld M., and Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol 24 (2006) 705-738
11. Graf T. Differentiation plasticity of hematopoietic cells. Blood 99 9 (2002) 3089-3101
12. Küppers R., and Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 16 (1998) 471-493
13. Küppers R., Klein U., Schwering I., et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 111 4 (2003) 529-537
14. Pileri S.A., Ascani S., Leoncini L., et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 55 3 (2002) 162-176
15. Schwering I., Bräuninger A., Klein U., et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma. Blood 101 4 (2003) 1505-1512
16. Dorfman D.M., Hwang E.S., Shahsafaei A., et al. T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma. Hum Pathol 36 1 (2005) 10-15
17. Atayar C., Poppema S., Blokzijl T., et al. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin's lymphomas. Am J Pathol 166 1 (2005) 127-134
18. Jundt F., Kley K., Anagnostopoulos I., et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99 8 (2002) 3060-3062
19. Stein H., Marafioti T., Foss H.D., et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97 2 (2001) 496-501
20. Ushmorov A., Ritz O., Hummel M., et al. Epigenetic silencing of the immunoglobulin heavy chain gene in classical Hodgkin's lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 104 10 (2004) 3326-3334
21. Ushmorov A., Leithäuser F., Sakk O., et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin's lymphoma. Blood 107 6 (2006) 2493-2500
22. Korkolopoulou P., Cordell J., Jones M., et al. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease. Histopathology 24 6 (1994) 511-515
23. Watanabe K., Yamashita Y., Nakayama A., et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 36 4 (2000) 353-361
24. Mathas S., Janz M., Hummel F., et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin's lymphoma. Nat Immunol 7 2 (2006) 207-215
25. Foss H.D., Reusch R., Demel G., et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94 9 (1999) 3108-3113
26. Renne C., Martin-Subero J.I., Eickernjager M., et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol 169 2 (2006) 655-664
27. Massari M.E., Rivera R.R., Voland J.R., et al. Characterization of ABF-1, a novel basic helix-loop-helix transcription factor expressed in activated B lymphocytes. Mol Cell Biol 18 6 (1998) 3130-3139
28. Rivera R., and Murre C. The regulation and function of the Id proteins in lymphocyte development. Oncogene 20 58 (2001) 8308-8316
29. Jundt F., Anagnostopoulos I., Förster R., et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99 9 (2002) 3398-3403
30. Nie L., Xu M., Vladimirova A., et al. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 22 21 (2003) 5780-5792
31. Smith E.M., Akerblad P., Kadesch T., et al. Inhibition of EBF function by active Notch signaling reveals a novel regulatory pathway in early B-cell development. Blood 106 6 (2005) 1995-2001
32. Pui J.C., Allman D., Xu L., et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11 3 (1999) 299-308
33. Sun X.H. Constitutive expression of the Id1 gene impairs mouse B cell development. Cell 79 5 (1994) 893-900
34. Bargou R.C., Emmerich F., Krappmann D., et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 12 (1997) 2961-2969
35. Bargou R.C., Leng C., Krappmann D., et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 10 (1996) 4340-4347
36. Hinz M., Löser P., Mathas S., et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97 9 (2001) 2798-2807
37. Hinz M., Lemke P., Anagnostopoulos I., et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196 5 (2002) 605-617
38. Luo J.L., Kamata H., and Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115 10 (2005) 2625-2632
39. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 6 (2004) 280-288
40. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
41. Barth T.F., Martin-Subero J.I., Joos S., et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin's lymphoma. Blood 101 9 (2003) 3681-3686
42. Krappmann D., Emmerich F., Kordes U., et al. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18 4 (1999) 943-953
43. Nonaka M., Horie R., Itoh K., et al. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 24 24 (2005) 3976-3986
44. Mathas S., Lietz A., Janz M., et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102 3 (2003) 1028-1034
45. Fiumara P., Snell V., Li Y., et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98 9 (2001) 2784-2790
46. Dürkop H., Latza U., Hummel M., et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68 3 (1992) 421-427
47. Annunziata C.M., Safiran Y.J., Irving S.G., et al. Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood 96 8 (2000) 2841-2848
48. Carbone A., Gloghini A., Gattei V., et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 85 3 (1995) 780-789
49. Mathas S., Lietz A., Anagnostopoulos I., et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199 8 (2004) 1041-1052
50. Horie R., Watanabe T., Ito K., et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 160 5 (2002) 1647-1654
51. Horie R., Watanabe T., Morishita Y., et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21 16 (2002) 2493-2503
52. Emmerich F., Theurich S., Hummel M., et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 201 3 (2003) 413-420
53. Emmerich F., Meiser M., Hummel M., et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94 9 (1999) 3129-3134
54. Wood K.M., Roff M., and Hay R.T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 16 16 (1998) 2131-2139
55. Jungnickel B., Staratschek-Jox A., Bräuninger A., et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 191 2 (2000) 395-402
56. Joos S., Granzow M., Holtgreve-Grez H., et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 103 4 (2003) 489-495
57. Martin-Subero J.I., Gesk S., Harder L., et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin's lymphoma. Blood 99 4 (2002) 1474-1477
58. Mathas S., Jöhrens K., Joos S., et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 106 13 (2005) 4287-4293
59. Martin-Subero J.I., Klapper W., Sotnikova A., et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Cancer Res 66 21 (2006) 10332-10338
60. Martin-Subero J.I., Wlodarska I., Bastard C., et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. Blood 108 1 (2006) 401-402 author reply 402-3
61. Mathas S., Hinz M., Anagnostopoulos I., et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin's lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21 15 (2002) 4104-4113
62. Watanabe M., Ogawa Y., Ito K., et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 163 2 (2003) 633-641
63. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 5 (2002) E131-E136
64. Szabowski A., Maas-Szabowski N., Andrecht S., et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 103 5 (2000) 745-755
65. Watanabe M., Sasaki M., Itoh K., et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin's lymphoma. Cancer Res 65 17 (2005) 7628-7634
66. Zheng B., Fiumara P., Li Y.V., et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102 3 (2003) 1019-1027
67. Janz M., Hummel M., Truss M., et al. Classical Hodgkin's lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 107 6 (2006) 2536-2539
68. Shuai K., and Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3 11 (2003) 900-911
69. Skinnider B.F., and Mak T.W. The role of cytokines in classical Hodgkin's lymphoma. Blood 99 12 (2002) 4283-4297
70. Skinnider B.F., Elia A.J., Gascoyne R.D., et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma. Blood 99 2 (2002) 618-626
71. Kube D., Holtick U., Vockerodt M., et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 98 3 (2001) 762-770
72. Trieu Y., Wen X.Y., Skinnider B.F., et al. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res 64 9 (2004) 3271-3275
73. Holtick U., Vockerodt M., Pinkert D., et al. STAT3 is essential for Hodgkin's lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19 6 (2005) 936-944
74. Weniger M.A., Melzner I., Menz C.K., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin's lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25 18 (2006) 2679-2684
75. Joos S., Küpper M., Ohl S., et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60 3 (2000) 549-552
76. Baus D., and Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin's lymphoma cells. Int J Cancer 118 6 (2006) 1404-1413
77. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 134 4 (2006) 366-384
78. Ambinder R. Infection and lymphoma. N Engl J Med 349 14 (2003) 1309-1311
79. Caldwell R.G., Wilson J.B., Anderson S.J., et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9 3 (1998) 405-411
80. Chapman A.L., and Rickinson A.B. Epstein-Barr virus in Hodgkin's disease. Ann Oncol 9 Suppl 5 (1998) S5-S16
81. Höpken U.E., Foss H.D., Meyer D., et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 99 4 (2002) 1109-1116
82. Nutt S.L., Heavey B., Rolink A.G., et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401 6753 (1999) 556-562
83. Mikkola I., Heavey B., Horcher M., et al. Reversion of B cell commitment upon loss of Pax5 expression. Science 297 5578 (2002) 110-113
84. Urbanek P., Wang Z.Q., Fetka I., et al. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79 5 (1994) 901-912
85. Souabni A., Cobaleda C., Schebesta M., et al. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 17 6 (2002) 781-793
86. Tagoh H., Ingram R., Wilson N., et al. The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction. EMBO J 25 5 (2006) 1070-1080
87. Delogu A., Schebesta A., Sun Q., et al. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 24 3 (2006) 269-281
88. Bain G., Maandag E.C., Izon D.J., et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 79 5 (1994) 885-892
89. Hu M., Krause D., Greaves M., et al. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 11 6 (1997) 774-785
90. Souabni A., Jochum W., and Busslinger M. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood 109 1 (2007) 281-289
91. Bain G., Engel I., Robanus Maandag E.C., et al. E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 17 8 (1997) 4782-4791
92. Yan W., Young A.Z., Soares V.C., et al. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol 17 12 (1997) 7317-7327
93. Hertel C.B., Zhou X.G., Hamilton-Dutoit S.J., et al. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin's lymphoma. Oncogene 21 32 (2002) 4908-4920
94. Akala O.O., and Clarke M.F. Hematopoietic stem cell self-renewal. Curr Opin Genet Dev 16 5 (2006) 496-501
95. Kato Y., Iwama A., Tadokoro Y., et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med 202 1 (2005) 169-179
96. Orlic D., Anderson S., Biesecker L.G., et al. Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci USA 92 10 (1995) 4601-4605
97. Tsai F.Y., Keller G., Kuo F.C., et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371 6494 (1994) 221-226
98. Antonchuk J., Sauvageau G., and Humphries R.K. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 109 1 (2002) 39-45
99. Zeng H., Yucel R., Kosan C., et al. Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. EMBO J 23 20 (2004) 4116-4125
100. Park I.K., Qian D., Kiel M., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 6937 (2003) 302-305
101. van der Lugt N.M., Alkema M., Berns A., et al. The Polycomb-group homolog Bmi-1 is a regulator of murine Hox gene expression. Mech Dev 58 1-2 (1996) 153-164
102. Duncan A.W., Rattis F.M., DiMascio L.N., et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6 3 (2005) 314-322
103. Reya T., Duncan A.W., Ailles L., et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423 6938 (2003) 409-414
104. Schneider E.M., Torlakovic E., Stuhler A., et al. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma. J Pathol 204 5 (2004) 538-545
105. Kapp U., Yeh W.C., Patterson B., et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189 12 (1999) 1939-1946
106. Kumano K., Chiba S., Shimizu K., et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 98 12 (2001) 3283-3289
107. Dukers D.F., van Galen J.C., Giroth C., et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 164 3 (2004) 873-881
108. Raaphorst F.M., van Kemenade F.J., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 157 3 (2000) 709-715
109. Nagel S., Burek C., Venturini L., et al. Comprehensive analysis of homeobox genes in Hodgkin's lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109 7 (2007) 3015-3023